These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 9576196)

  • 21. Minimal residual disease after intensive induction therapy in childhood acute lymphoblastic leukemia predicts outcome.
    Gruhn B; Hongeng S; Yi H; Hancock ML; Rubnitz JE; Neale GA; Kitchingman GR
    Leukemia; 1998 May; 12(5):675-81. PubMed ID: 9593264
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Minimal residual disease after induction is the strongest predictor of prognosis in intermediate risk relapsed acute lymphoblastic leukaemia - long-term results of trial ALL-REZ BFM P95/96.
    Eckert C; von Stackelberg A; Seeger K; Groeneveld TW; Peters C; Klingebiel T; Borkhardt A; Schrappe M; Escherich G; Henze G
    Eur J Cancer; 2013 Apr; 49(6):1346-55. PubMed ID: 23265714
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of CD58 in normal, regenerating and leukemic bone marrow B cells: implications for the detection of minimal residual disease in acute lymphocytic leukemia.
    Veltroni M; De Zen L; Sanzari MC; Maglia O; Dworzak MN; Ratei R; Biondi A; Basso G; Gaipa G;
    Haematologica; 2003 Nov; 88(11):1245-52. PubMed ID: 14607753
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Detection of residual disease in pediatric B-cell precursor acute lymphoblastic leukemia by comparative phenotype mapping: method and significance.
    Dworzak MN; Fritsch G; Panzer-Grümayer ER; Mann G; Gadner H
    Leuk Lymphoma; 2000 Jul; 38(3-4):295-308. PubMed ID: 10830736
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood.
    van Dongen JJ; Seriu T; Panzer-Grümayer ER; Biondi A; Pongers-Willemse MJ; Corral L; Stolz F; Schrappe M; Masera G; Kamps WA; Gadner H; van Wering ER; Ludwig WD; Basso G; de Bruijn MA; Cazzaniga G; Hettinger K; van der Does-van den Berg A; Hop WC; Riehm H; Bartram CR
    Lancet; 1998 Nov; 352(9142):1731-8. PubMed ID: 9848348
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Flow cytometric analysis of normal B cell differentiation: a frame of reference for the detection of minimal residual disease in precursor-B-ALL.
    Lúcio P; Parreira A; van den Beemd MW; van Lochem EG; van Wering ER; Baars E; Porwit-MacDonald A; Bjorklund E; Gaipa G; Biondi A; Orfao A; Janossy G; van Dongen JJ; San Miguel JF
    Leukemia; 1999 Mar; 13(3):419-27. PubMed ID: 10086733
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Monitoring treatment response of childhood precursor B-cell acute lymphoblastic leukemia in the AIEOP-BFM-ALL 2000 protocol with multiparameter flow cytometry: predictive impact of early blast reduction on the remission status after induction.
    Ratei R; Basso G; Dworzak M; Gaipa G; Veltroni M; Rhein P; Biondi A; Schrappe M; Ludwig WD; Karawajew L;
    Leukemia; 2009 Mar; 23(3):528-34. PubMed ID: 19020543
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia.
    Coustan-Smith E; Sancho J; Hancock ML; Razzouk BI; Ribeiro RC; Rivera GK; Rubnitz JE; Sandlund JT; Pui CH; Campana D
    Blood; 2002 Oct; 100(7):2399-402. PubMed ID: 12239148
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combined use of reverse transcriptase polymerase chain reaction and flow cytometry to study minimal residual disease in Philadelphia positive acute lymphoblastic leukemia.
    Muñoz L; López O; Martino R; Brunet S; Bellido M; Rubiol E; Sierra J; Nomdedéu JF
    Haematologica; 2000 Jul; 85(7):704-10. PubMed ID: 10897122
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Flow cytometric detection of minimal residual disease in pre-cursor-B-acute lymphoblastic leukemia on the basis of phenotypic aberrancies on minor leukemic cell populations].
    Wu M; Sun XF; Xu ZM; Zhang XY; Li FR; Wang XG; Chen XL; Lin HQ; Wen HG; Sun X; Song TW
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Aug; 13(4):557-62. PubMed ID: 16129033
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Dynamically monitoring minimal residual disease in acute leukemia after complete remission by multiparameter flow cytometry and its relation with prognosis].
    Sun NN; Gan SL; Sun H; Zhang QT; Liu YF; Xie XS
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Apr; 21(2):339-42. PubMed ID: 23628028
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation.
    Pérez-Simón JA; Caballero D; Diez-Campelo M; Lopez-Pérez R; Mateos G; Cañizo C; Vazquez L; Vidriales B; Mateos MV; Gonzalez M; San Miguel JF
    Leukemia; 2002 Aug; 16(8):1423-31. PubMed ID: 12145680
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Prognostic value of both detection of lymphoblasts in the period of early treatment and minimal residual disease in childhood acute lymphoblastic leukemia].
    Tie LJ; Gu LJ; Song DL; Jiang LM; Xue HL; Tang JY; Dong L; Pan C; Chen J; Ye H; Wang YP; Chen J
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):6-9. PubMed ID: 15946500
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia.
    Coustan-Smith E; Behm FG; Sanchez J; Boyett JM; Hancock ML; Raimondi SC; Rubnitz JE; Rivera GK; Sandlund JT; Pui CH; Campana D
    Lancet; 1998 Feb; 351(9102):550-4. PubMed ID: 9492773
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The significance of detection of minimal residual disease in childhood acute lymphoblastic leukaemia.
    Potter MN; Steward CG; Oakhill A
    Br J Haematol; 1993 Mar; 83(3):412-8. PubMed ID: 8485046
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical significance of minimal residual disease at day 15 and at the end of therapy in childhood acute lymphoblastic leukaemia.
    Sutton R; Venn NC; Tolisano J; Bahar AY; Giles JE; Ashton LJ; Teague L; Rigutto G; Waters K; Marshall GM; Haber M; Norris MD;
    Br J Haematol; 2009 Aug; 146(3):292-9. PubMed ID: 19500099
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Effects of minimal residual disease level on day 33 of remission induction and IKZF1 genotype on the survival of children with B-lineage acute lymphoblastic leukemia].
    Kuang WY; Zheng MC; Li WL; Yang HX; Zhang BS; Wu P
    Zhongguo Dang Dai Er Ke Za Zhi; 2018 Jul; 20(7):538-542. PubMed ID: 30022754
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Comparison of the immunophenotype of patients with B lineage acute lymphoblastic leukemia at diagnosis and relapse].
    Liu YR; Chang Y; Fu JY; Cheng YF; Zhang LP; Li LD; Wang H; Liu GL; Chen SS; Huang XJ; Lu DP
    Zhonghua Xue Ye Xue Za Zhi; 2006 May; 27(5):335-8. PubMed ID: 16875586
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Monitoring of minimal residual disease in adult acute myeloid leukemia using peripheral blood as an alternative source to bone marrow.
    Maurillo L; Buccisano F; Spagnoli A; Del Poeta G; Panetta P; Neri B; Del Principe MI; Mazzone C; Consalvo MI; Tamburini A; Ottaviani L; Fraboni D; Sarlo C; De Fabritiis P; Amadori S; Venditti A
    Haematologica; 2007 May; 92(5):605-11. PubMed ID: 17488683
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The limited possibility of using a simplified approach to detect minimal residual disease by the flow cytometry technique in children with precursor B-lineage acute lymphoblastic leukemia].
    Popov AM; Verzhbitskaia T; Tsaur GA; Shorikov EV; Tsvirenko SV; Savel'ev LI; Fechina LG
    Klin Lab Diagn; 2011 Mar; (3):25-9. PubMed ID: 21574456
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.